Epidiolex Shows Promise in Latest Study

Photo Credit: Marijuana Investor News

Photo Credit: Marijuana Investor News

The latest study surrounding Epidiolex, a CBD-derived medication produced by GW Pharmaceuticals, has shown promising results in the treatment of intractable seizures. The trial lasted three months and involved 313 children who suffered from seizure disorders and did not experience relief from conventional treatment methods. The ages of the children varied, but the average age was about 11 years old. Participants were given Epidiolex in addition to their regular medications, and approximately 84% of the children witnessed a reduction in grand mal seizures by an average of about 50%. Lead author of the study, Dr. Orrin Devinsky, said 9% of all of the patients, and 13% who suffered from Dravet Syndrome specifically, became seizure free, something that they had never been before.

That being said, the new medication did not work for everyone. About 16% of participants eventually withdrew from the study due to a lack of improvement or to adverse side effects like diarrhea, fatigue, decreased appetite or altered liver enzymes. In addition, the study is not without its limitations. Researchers and participants knew what medication was being administered, which at times produces biased results. The study also neglected to include a control group to look at whether or not a placebo effect was involved. In order to get a truly accurate study, Epidiolex should be researched within a double-blinded and controlled study. Nonetheless, researchers are still hopeful about the medication and hope to continue their research.

This information has been provided by Marijuana Investor News and approved by our Chief Medical Officer.